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ABSTRACT
Background. Generalized anxiety disorder is a common condition of excessive worry and tension
which tends to run a chronic course associated with signiﬁcant psychiatric and medical problems.
Cognitive behaviour therapy (CBT) has been shown to be of clinical value in about 50%of cases with
treatment gains maintained over follow-up periods ranging from 6 to 12months. The potential value
of CBT over the longer term has not been subject to rigorous investigation.
Method. Results are reported of 8–14 year follow-up of two randomized controlled trials of cog-
nitive-behaviour therapy for generalized anxiety disorder employing structured interview with an
assessor blind to initial treatment condition. Comparison groups includedmedication and placebo in
one study based in primary care, and analytical psychotherapy in the other based in secondary care.
Follow-up samples (30% and 55% of trial entrants) were broadly representative of the original
cohorts.
Results. Overall, 50% of participants were markedly improved of whom 30–40% were recovered
(i.e. free of symptoms). Outcome was signiﬁcantly worse for the study based in secondary care
in which the clinical presentation of participants was more complex and severe. For a minority
(30–40%), mainly from the secondary care study, outcome was poor. Treatment with CBT was
associated with signiﬁcantly lower overall severity of symptomatology and less interim treatment, in
comparison with non-CBT conditions, but there was no evidence that CBT inﬂuenced diagnostic
status, probability of recovery or patient perceptions of overall improvement.
Conclusions. Both CBT and the complexity and severity of presenting problems appear to inﬂuence
the long-term outcome of GAD.
INTRODUCTION
Generalized anxiety disorder (GAD) is a preva-
lent condition of excessive worry and tension
which typically runs a ﬂuctuating and often
chronic course associated with heavy demands
onhealth service resources (Ballenger et al. 2001).
The duration and severity of particular episodes
are inﬂuenced by a range of biological and
psychosocial variables including psychological
therapy (Hoehn-Saric et al. 1995). Fisher &
Durham (1999) analysed the clinical signiﬁcance
of changes following psychological therapy for
GAD, using Jacobson criteria, and found that
overall rates of recovery at 6 month follow-up
were relatively modest (40%) although highest
with individual cognitive-behavioural therapy
(CBT) and applied relaxation (50–60%). Bor-
kovec & Ruscio (2001) reviewed 13 controlled
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clinical trials of psychological therapy for GAD
and found that CBTwas associated with the low-
est dropout rates and the largest within-group
andbetween-groupeﬀect sizes relative toall other
comparison conditions. They found consistent
evidence that therapeutic gains following CBT
were maintained but length of follow-up aver-
aged only 9 months with a range of 6 to 12
months.
It is worth noting that all of the studies in these
reviews were conducted by clinical researchers
with a primarily cognitive-behavioural orien-
tation; a less promising picture is reported by
Seivewright and colleagues who conducted a
5-year follow-up of a cohort of 210 psychiatric
out-patients suﬀering fromGAD, panic disorder
or dysthymic disorder and randomized to medi-
cation, CBTor self-help (Seivewright et al. 1998).
Sixty per cent had a broadly favourable out-
come with the remainder handicapped either
intermittently or continuously throughout the
follow-up period. Initial diagnosis and original
treatment were found to be of no predictive value
although a further analysis found that over half
the patients had been treated by therapists of
uncertain competence and that lasting beneﬁt
was associated with CBT delivered by therapists
rated as competent during supervision (Kingdon
et al. 1996).
Clearly CBT, with its emphasis on teaching
active coping skills, has the potential to inﬂuence
the long-term course of GAD. Current evidence,
however, consists mainly of postal question-
naires of symptom severity over relatively short
follow-up periods, with variable deﬁnitions of
outcome, and is too limited to draw ﬁrm con-
clusions (Roth & Fonagy, 1996; Tyrer, 2000).
Moreover, studies of the natural history of
anxiety disorders tend to suggest that the long-
termoutcome ofGAD is generally less good than
other types of anxiety disorder with less than
one-third achieving recovery (Ormel et al. 1993;
Quinton et al. 1995). A true picture of the power
of psychological therapies to alter speciﬁc con-
ditions will only emerge from comprehensive
assessments of representative samples of patients
randomized to diﬀerent treatment conditions
and followed up over a number of years.
In this paper we report results from an ex-
tended follow-up of two clinical trials of CBT for
GAD (Power et al. 1990; Durham et al. 1994) in
which self-report data were supplemented by a
structured interview with an assessor blind to
initial treatment condition. Two broad questions
are addressed: (1) What is the long-term out-
come of patients who participated in these two
clinical trials? ; and (2) Does treatmentwithCBT
confer an advantage relative to medication and
alternative psychotherapy?
METHOD
Participants
Study 1 participants took part in a randomized,
controlled trial of diazepam (DZ), placebo (PL),
cognitive behavioural therapy alone (CBT),
cognitive behavioural therapy plus diazepam
(CBT+DZ) and cognitive behavioural therapy
plus placebo (CBT+PL). The trial was based
at the Anxiety and Stress Centre, University of
Stirling, between1985and1988.All patientswere
recruited from primary care health centres and
had a primary diagnosis of generalized anxiety
disorder (GAD) according to DSM-III criteria
(American Psychiatric Association, 1980). A full
description of the trial can be found in the orig-
inal report (Power et al. 1990). Study 2 partici-
pants took part in a randomized, controlled trial
of cognitive therapy (CT), analytical psycho-
therapy (AP) or anxiety management training
(AMT). The trial was based at theDepartment of
Psychiatry, University of Dundee between 1989
and 1991. Patients were recruited from either
general physicians in primary care or from psy-
chiatrists in secondary care and had a primary
diagnosis of GAD according to DSM-III-R cri-
teria (American Psychiatric Association, 1987).
A full description of the trial can be found in the
original report (Durham et al. 1994). In neither
study was co-morbidity controlled for in allo-
cating cases to treatment groups.
In both studies there was an attempt to follow-
up all participants since it was felt that drop-outs,
non-attenders and completers were equally im-
portant in gaining a comprehensive view of the
long-term course of GAD on an intention-to-
treat basis. Of the 111 patients entering Study 1,
10 had failed to attend for treatment, 18 had
dropped out of treatment before the mid-point
and 83 had completed treatment. Seventeen of
these 111 patients were either untraceable at
long-term follow-up or had died in the interim
period, and one GP refused permission to con-
tact a patient. Of the 93 patients who were
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contacted, 33 (30%) took part in the long-term
follow-up study, with 28 of these attending for
full diagnostic interview. Of the 110 patients
entering Study 2, 11 had failed to attend for
treatment, 19 had dropped out of treatment and
80 had completed treatment. Sixteen of these 110
patients were either untraceable at long-term
follow-up or had died in the interim period, and
one GP refused permission to contact a patient.
Of the 93 patients who were contacted, 61 (55%)
took part in the long-term follow-up study, with
51 of these attending for full diagnostic inter-
view.
Participant characteristics
The follow-up sample in Study 1 consisted of 14
men and 19 women with a mean age of 53 years
(range 30 to 72)whowere interviewed between 11
and 14 years following discharge from treatment
in the original trial. The sample in Study 2 con-
sisted of 20 men and 41 women with a mean age
of 48 years (range 27 to 71) whowere interviewed
between 8 and 10 years following discharge from
treatment in the original trial. Study 2 patients
had signiﬁcantly higher scores on a seven-point
measure of degree of social deprivation based on
postcode sector (Carstairs&Morris, 1991) (mean
diﬀerence=1.2, 95% CI (0.5, 1.9), P<0.01) and
had a greater chronicity of disorder as might be
expected from the longer duration criterion used
in DSM-III-R in comparison with DSM-III
(6 months versus 1 month).
Comparison of participants and non-participants
In view of the large number of patients who were
unavailable to follow-up, or who failed to re-
spond to a postal invitation to take part, an
exhaustive analysis was made of the character-
istics of participants and non-participants in
respect of baseline demographics, allocation to
treatment conditions, baseline symptomatic
state and response to treatment. Full details of
these comparisons are available from the senior
author. In summary, there were no signiﬁcant
diﬀerences between follow-up participants and
non-participants with regard to age, gender,
marital status, social deprivation, frequency of
visits to GPs (primary care physicians) before
and after the original trials, presence of co-
morbid diagnoses at the time of the original trial,
family history of mental health problems, orig-
inal measures of symptom severity, proportions
in original treatment conditions, proportions on
medication for anxiety at the time of the original
trials or proportions with previous psychological
or psychiatric treatment prior to the original
trials.
Participants from Study 2, however, were
signiﬁcantly more likely than non-participants
to have had completed initial treatment (84%
v. 59%) (x2(2)=8.4, P<0.05). Participants from
Study 1were signiﬁcantlymore likely to have had
a positive response to previous drug treatment
for anxiety disorders than non-participants
(88% v. 59%) (x2(1)=5.8, P<0.05) and to have
had a shorter duration of current episode of
anxiety at the time of the trial (either<1 month
or between 1 and 3 months) than non-partici-
pants (73.1% v. 41.7%; x2(3)=9.1, P<0.05).
Procedure
The same overall procedure was followed in both
studies as approved by the respective medical
research ethics committees in the two localities.
Patient details from the original trials were veri-
ﬁedwith localmedical records and attempts were
made to trace patients who had moved using
central medical records where available. Per-
mission to contact all successfully traced patients
was then sought from each patient’s general
medical practitioner and if this was refused
(N=2) the patient was excluded. Patients resid-
ing in Scotland were contacted by letter and
invited to complete the main outcome ques-
tionnaires and to participate in a one-hour in-
terview if they were in reasonable travelling
distance. One patient living outside Scotlandwas
sent questionnaires only. Every eﬀort was made
to see participants at a time and place of their
convenience either at the research base, a local
clinic or the patient’s home.
Interviews were all conducted by the same
research psychologist (J.C.) who was blind to
treatment condition until the very end of the
interview when there was a brief assessment of
attitudes to the original treatment to be reported
in a separate paper. The interview consisted of :
(1) the Anxiety Disorders Interview Schedule IV
(ADIS-IV; Brown et al. 1994) to assess diag-
nostic status according to DSM-IV criteria ;
and (2) an assessment of amount of treatment
for mental health problems since participation
in the original trial. The following four-point
scale was used to categorize the amount of
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patient-reported interim treatment for anxiety
with either medication or psychological therapy:
(1) none; (2) little – treatment over one short
time period; (3) moderate – treatment over sev-
eral years ; and (4) a lot – treatment for the ma-
jority of the intervening period. This scale has
some similarities to that used by Seivewright and
colleagues (1998) to categorize overall outcome
on the basis of case note review but, unlike their
scale, excludes symptom severity and social dys-
function. Many patients had diﬃculty recalling
the precise nature of treatment received and it
was felt that reliable data could only be collected
for the overall amount. Patient responses on
amount of interim treatment were cross-checked
with medical case notes for 36% (N=12) of the
sample in Study 1. In eight cases (67%) results
tallied exactly, and in the remaining four cases
three had underestimated the amount of treat-
ment received by one category, and one had
underestimated it by two categories.
Those patients who failed to respond to the
initial letter within 3 weeks were sent a remin-
der, which included the main outcome question-
naires. This letter oﬀered those patients not
wishing to attend an interview the additional
options of either a telephone interview plus ques-
tionnaires or the completion of questionnaires
only.
Measures
Outcome measures administered to all partici-
pants were as follows.
Clinical Global Severity (CGS )
This is a component of the ADIS-IV and was
measured on 0–8 point scale (0=no evidence of
disorder, 4=deﬁnitely disturbing/disabling, and
8=very severely disturbing/disabling).
Brief Symptom Inventory (BSI ) (Derogatis,
1993)
This is a shortened version of the SCL-90 and
a global measure of current symptomatic state,
measured on a ﬁve-point scale (0–4). The BSI
global severity index (BSI-GSI), representing a
mean score for all completed items, was used
in the current analysis. Jacobson criterion (c)
(Jacobson & Truax, 1991) was used to identify
clinically signiﬁcant change on this measure
deﬁned as a reliable change between pre- and
follow-up scores and a score below the cut-oﬀ
point for normative functioning. For criterion
(c), the cut-oﬀ is calculated as the mid-point
between two standard deviations below the pre-
treatment mean and two standard deviations
above the mean for the normal population.
Clinical Global Improvement (CGI )
This is a patient-rated seven-point scale mea-
suring change in condition since the original trial
using the following categories : marked/moder-
ate/mild improvement/no change/mild/moder-
ate/marked deterioration (Guy, 1982).
UK SF-36 version 2 (Jenkinson et al. 1999)
The SF-36 Health Survey was developed by
Ware and colleagues (1993) as a measure of
health status comprising eight subscales : physi-
cal role, physical functioning, emotional role,
vitality, bodily pain, mental health, social role
and general health. Jenkinson et al. (1999) de-
veloped norms for a UK population, using a
version of the SF-36, which has minor wording
diﬀerences from the original measure, in order
to make it more acceptable to UK populations.
The physical (SF36-PC) and mental (SF36-MC)
components of the SF-36, originally derived via
factor analysis, summarize the eight original
subscales. The SF36-MC was used in the current
analysis.
In addition the clinician-rated Hamilton
Rating Scale for Anxiety (HAM-A) (Hamilton,
1959) was included for Study 1 only, using the
structured scoring system used in the original
trial (cf. Power et al. 1985).
Because there was no overlap in self-report
questionnaires used in the original two studies a
main outcomemeasure speciﬁc to each studywas
also included as follows: the Kellner & Sheﬃeld
(1973) Symptom Rating Test (SRT), a ques-
tionnaire designed to measure changes in symp-
toms of distress in neurotic patients, was used
in Study 1 but not Study 2; and the trait version
of the State Trait Anxiety Inventory (STAI-T)
(Spielberger et al. 1983) was used in Study 2 but
not Study 1.
RESULTS
Changes in symptom severity from pre-treatment
to follow-up on original outcome measures
Table 1 shows themeans and standard deviations
of the main outcome measures before treatment
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and at long-term follow-up for each treatment
group. Only those patients for whom scores were
available at both time points are included in
Table 1. For the purposes of analyses the treat-
ment groups were amalgamated into CBT and
non-CBT for each study as follows: Study 1 –
CBT, CBT+DZ, CBT+PL v. DZ and PL;
Study 2 – CT and AMT v. AP. The groups were
amalgamated because the number of patients
in each treatment group was small and separate
one-way ANOVAs on the diﬀerences between
the individual treatment groups did not reveal
any signiﬁcant diﬀerences on any follow-up out-
comemeasure in either study. Table 1 shows that
there was a reduction in symptom severity in all
treatment groups in both studies. Paired t tests
on the change from pre-treatment to long-term
follow-up show a signiﬁcant improvement in
the combined CBT group in Study 1 on both the
HAM-A and the SRT, but no signiﬁcant im-
provement on either measure for the non-CBT
group. The same analysis showed a signiﬁcant
improvement for both theCBTand the non-CBT
groups in Study 2 on both the BSI-GSI and the
STAI-T. Although in general the CBT groups
appeared to improve more than the non-CBT
groups, independent t tests revealed these dif-
ferences to be non-signiﬁcant in both studies.
Proportions sustaining and achieving recovery
from 6 month to long-term follow-up
Table 2 shows the proportion of long-term fol-
low-up participants who achieved or maintained
recovery according to Jacobson criteria on the
main self-report outcome measure for each
study, broken down by CBT group. Jacobson
deﬁned clinically signiﬁcant change as achieving
a score below a cut-oﬀ point representative of
normative functioning, together with a reliable
degree of change between pre-treatment and
follow-up scores (Jacobson & Truax, 1991). In
both studies we repeated the analysis using the
Table 1. Changes in symptom severity from pre-treatment to long-term follow-up on original outcome
measures for each study
Treatment
group N
Pre-treatment
Mean (S.D.)
Long-term follow-up
Mean (S.D.) Diﬀerence (95% CI)
Study 1
HAM-A#
CBT alone 7 14.7 (3.4) 7.9 (3.1)
CBT+DZ 8 12.9 (5.8) 9.1 (6.5)
CBT+PL 4 16.0 (4.1) 9.0 (6.7)
CBT group 19 14.2 (4.6) 8.6 (5.2) x5.6*** x7.7,x3.5
DZ only 7 13.4 (6.4) 11.4 (5.6)
PL only 3 16.7 (2.1) 10.3 (7.5)
Non-CBT 10 14.4 (5.6) 11.1 (5.8) x3.3 x9.1, 2.5
SRT#
CBT alone 8 35.4 (18.3) 18.9 (13.3)
CBT+DZ 9 29.2 (16.8) 19.8 (13.0)
CBT+PL 4 32.8 (12.5) 18.5 (16.3)
CBT group 21 32.2 (16.2) 19.2 (13.0) x13.0** x20.2,x5.9
DZ only 7 30.1 (14.0) 23.0 (17.5)
PL only 4 38.0 (9.3) 29.8 (17.8)
Non-CBT 11 33.0 (12.6) 25.4 (17.0) x7.6 x16.9, 1.8
Study 2
BSI-GSI#
CT 22 1.73 (0.7) 1.15 (0.8)
AMT 11 1.45 (0.5) 1.16 (0.8)
CBT group 33 1.64 (0.6) 1.15 (0.8) x0.48** x0.71,x0.25
AP 23 1.74 (0.6) 1.37 (0.8)
Non-CBT 23 1.74 (0.6) 1.37 (0.8) x0.38** x0.73,x0.02
STAI-T#
CT 22 58.6 (9.9) 49.8 (14.1)
AMT 12 52.8 (14.0) 48.5 (12.9)
CBT group 34 56.6 (11.6) 49.4 (13.5) x7.2** x11.1,x3.3
AP 23 61.1 (6.2) 49.2 (13.9)
Non-CBT 23 61.1 (6.2) 49.2 (13.9) x11.9*** x16.7,x7.1
# Lower scores are more favourable.
Paired t tests : ** P<0.01; *** P<0.001.
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Jacobson criteria adopted in the original trials.
For study 1, a cut-oﬀ point of 15 on the SRTwas
used, which was equivalent to two standard de-
viations below the sample pre-treatment mean.
In Study 2, we used Jacobson criterion (c) which
gave a cut-oﬀ score of 47 on the STAI-T, together
with a reliable change index equating to a change
from pre-treatment to long-term follow-up of
o8.
Table 2 shows the actual numbers of long-term
follow-up participants achieving or maintaining
recovery, also shown as a percentage of the total
number of participants in each group. It can be
seen in Study 1, that while the majority of pa-
tients (70–80%) had achieved clinically signiﬁ-
cant change on the SRT at 6 month follow-up,
less than half of these (i.e. 10 out of 23) had
maintained their recovery at long-term follow-
up. In addition, of those not recovered at 6
month follow-up, only one patient had achieved
recovery status in the interim period, and the
overall recovery rate at long-term follow-up was
therefore modest (30–40%).
In Study 2, less than a quarter of long-term
follow-upparticipants had achieved recovery at 6
month follow-up according to Jacobson criteria
on the STAI-T, andonly half of these (i.e. 5 out of
10) had maintained that recovery to long-term
follow-up. In Study 2, 14 patients who were not
recovered on the STAI-T at 6 month follow-up
did achieve recovery at long-term follow-up,
giving overall recovery rates at long-term follow-
up of 36–42%.
Finally, it can be seen from Table 2 that there
are no appreciable diﬀerences in recovery rates
between the CBT and non-CBT groups for either
study.
Comparison of Study 1 and Study 2
Although nearly one half of the total sample
received no DSM-IV diagnosis the proportion
of Study 1 patients with no diagnosis was nearly
double that of Study 2 (69% v. 37%) and this
diﬀerence was signiﬁcant. Of those patients who
did meet diagnostic criteria for one or more
disorders the majority were co-morbid (79%)
with co-morbidity being much more common in
Study 2 than in Study 1. The nature of the di-
agnoses is of some interest. Only one individual
in the total sample had a pure diagnosis of GAD
and there is evidence of drift toward non-
GAD diagnoses with 10% of the total sample
meeting criteria for a single non-GAD diagnosis
(social phobia=3, panic disorder=3, hypochon-
driasis=1, depression=1, simple phobia=2)
and 8%meeting criteria for more than one non-
GAD diagnosis.
Nearly two-thirds of the total sample reported
receiving little or no interim treatment formental
health problems since the original trials with
20% reporting a moderate amount and 16%
reporting a lot. Again, there is a signiﬁcant dif-
ference in the pattern of interim treatment across
the two studies with a sizeable minority of Study
2 patients receiving a lot of treatment (23%) and
a negligible proportion so doing in Study 1 (3%)
(x2(1)=6.3, P<0.05).
Across both studies, the proportion of patients
deﬁned as ‘recovered’ or ‘ in remission’ on the
Brief Symptom Inventory (BSI) was measured
Table 2. Recovery rates at 6-month and long-term follow-up using Jacobson criteria applied to the
primary self-report outcome measure in each study
Treatment
group
6 mth follow-up
Long-term follow-up
Recovery Recovery Recovery
Recovered maintained achieved rate overall
N (%)* N (%)* N (%)* N (%)*
Study 1: SRT#
CBT 16 (80) 7 (35) 1 (5) 8 (40)
Non-CBT 7 (70) 3 (30) 0 (0) 3 (30)
Study 2: STAI-T$
CBT 8 (26) 3 (10) 8 (26) 11 (36)
Non-CBT 2 (11) 2 (11) 6 (32) 8 (42)
* The number achieving or maintaining recovery as a percentage of long-term follow-up participants in each group as follows: Study 1
CBT=20, non-CBT=10; Study 2 CBT=31, non-CBT=19.
# SRT, Kellner & Sheﬃeld Symptom Rating Test.
$ STAI-T, trait version of the State Trait Anxiety Inventory.
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in terms of both the percentage of participants
achieving caseness as deﬁnedbyDerogatis (1993)
and the percentage of participants below the cut-
oﬀ (0.98) for clinically signiﬁcant change as de-
ﬁned by Jacobson criterion (c) as calculated in
Study 2 (Jacobson & Truax, 1991). The reliable
change index was included for Study 2 only
(equating toachange frompre-treatment to long-
term follow-up of o0.51) since pre-treatment
scores on the BSI were unavailable for Study 1. It
can be seen that the majority of participants
remained symptomatic in varying degrees. Al-
though higher proportions of Study 1 than Study
2 patients achieved recovery status the diﬀer-
ences were not signiﬁcant.
Table 3 also shows that there were signiﬁcant
diﬀerences in the patient ratings of improvement
between the studies. About one half of the total
sample described themselves as markedly im-
proved, with 69% in Study 1 compared with
43% in Study 2. This diﬀerence is signiﬁcant
(x2(1)=5.3, P<0.05).
Comparison of CBT and non-CBT groups
There were no signiﬁcant diﬀerences with respect
to diagnostic status. There was a tendency for
patients in the non-CBT groups to have had
a greater amount of interim treatment, and,
although the overall x2 was not signiﬁcant,
only 9% of the CBT group reported having a lot
of treatment versus 26% of the non-CBT group,
and this diﬀerence was signiﬁcant (x2(1)=5.1,
P<0.05). A higher percentage of those in the
CBT group were deﬁned as ‘non-cases ’ (Dero-
gatis, 1993) on the BSI (33% v. 16%) and this
diﬀerence approached signiﬁcance (P=0.059)
(see Table 3). In addition a higher percentage of
participants from the CBT group had achieved
the cut-oﬀ score on the BSI as deﬁned by
Jacobson criterion (c) for Study 2 (48% v. 34%),
but this diﬀerencewas not signiﬁcant. Therewere
no diﬀerence between the CBT and non-CBT
groups in patient perceptions of overall im-
provement.
Cross-sectional analysis of outcome at
long-term follow-up on common measures of
overall symptom severity
The mean scores of the main outcome measures
of symptom severity at long-term follow-up (i.e.
the CGS, BSI-GSI and SF36-MC) are shown in
Table 4. These are broken down by amalgamated
CBT and non-CBT groups for each study. Table
4 also shows the pre- and post-treatment scores
on the primary outcome measure used in each
of the original trials (i.e. the HAM-A for Study 1
Table 3. Patient status at long-term follow-up by study and by amalgamated CBT and
non-CBT groups
Study 1 v.
Total sample
CBT v.
Study 1 Study 2 Study 2 CBT Non-CBT All Non-CBT
N (%) N (%) df x2 N (%) N (%) N (%) df x2
Diagnostic status
None 20 (69) 20 (37) 24 (48) 16 (48) 40 (48)
One diagnosis 4 (14) 5 (9) 5 (10) 4 (12) 9 (11)
Two or more diagnoses 5 (17) 29 (54) 2 10.5** 21 (42) 13 (40) 34 (41) 2 0.1
Interim treatment
None/little 23 (70) 37 (61) 38 (68) 22 (58) 60 (64)
Moderate 9 (27) 10 (16) 13 (23) 6 (16) 19 (20)
A lot 1 (3) 14 (23) 2 6.9* 5 (9) 10 (26) 15 (16) 2 5.3
Clinically signiﬁcant change on BSI-GSI
BSI non-case# 11 (33) 13 (22) 1 1.4 18 (33) 6 (16) 24 (26) 1 3.6
BSI Jacobson criteria$ 16 (48) 23 (39) 1 0.8 26 (48) 13 (34) 39 (42) 1 1.8
Patient ratings of improvement
Marked improvement 20 (69) 23 (43) 25 (50) 18 (55) 43 (52)
Moderate/mild improvement 8 (28) 15 (28) 16 (32) 7 (21) 23 (28)
No change/worse 1 (3) 16 (30) 2 8.8* 9 (18) 8 (24) 17 (20) 2 1.3
# BSI caseness as deﬁned by Derogatis (1993).
$ Jacobson criterion (c) as deﬁned for Study 2 used across both studies (without reliable change index).
* P<0.05; ** P<0.01.
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and the BSI-GSI for Study 2) together with the
Direct Maximum Likelihood (DML) estimates
of these statistics resulting from a missing data
analysis described below.
It can be seen that participants in Study 1
had more favourable scores than participants
in Study 2 on all three outcome measures at
long-term follow-up. A MANOVA showed the
diﬀerences between studies to be signiﬁcant
(F(3,73)=4.1, P<0.05) and signiﬁcant univari-
ate eﬀects were found on the CGS (F(1,75)=
10.6, P<0.01) and the SF36-MC (F(1,75)=7.4,
P<0.01).
A MANOVA on the diﬀerences between the
CBT and non-CBT groups combining the data
from the two studies at long-term follow-up
on the CGS, BSI-GSI and SF36-MC yielded a
signiﬁcant overall F(3,73)=4.4, P<0.01). Sig-
niﬁcant univariate eﬀects were found on the
SF36-MC (F(1,75)=8.1, P<0.01) and the BSI-
GSI (F(1,75)=5.8, P<0.05).
Missing data analyses
As only 52% of the patients in the study parti-
cipated in the long-term follow-up an attempt
wasmade to determinewhat the datawould have
been if there was no missing data, by obtaining
direct maximum likelihood (DML) estimates of
the means of the CBT and non-CBT groups in
each study using pre-, post- and follow-up scores.
For each variable the method adjusts the means
to take account of how missing patients scored
on the remaining variables used in the analysis. It
assumes that the data is random with respect to
all other variables. The analysis is recommended
inAllison (2001).We used theAMOSpackage to
perform the calculations and to perform stat-
istical tests on the diﬀerences between the CBT
and non-CBT groups on the means of the long-
term follow-up variables. The two studies had
to be analysed separately because diﬀerent mea-
sures were taken at the start of the studies. Owing
to the limited amount of data available AMOS
was unable to estimate themeans simultaneously
on all the available variables. It was therefore
decided to perform the missing data analysis
using the pre- and post-treatment scores for the
primary outcome measure used in each original
study (i.e. the HAM-A for Study 1 and the BSI-
GSI for Study 2) together with the long-term
follow-up outcome measures used across both
studies (i.e. the BSI-GSI, CGS and SF-36-MC).
T
a
b
le
4
.
O
b
se
rv
ed
a
n
d
es
ti
m
a
te
d
m
ea
n
s
a
n
d
st
a
n
d
a
rd
er
ro
rs
o
f
th
e
m
ea
n
s
fo
r
sy
m
p
to
m
se
ve
ri
ty
m
ea
su
re
s
a
t
lo
n
g
-t
er
m
fo
ll
o
w
-u
p
b
y
a
m
a
lg
a
m
a
te
d
C
B
T
a
n
d
n
o
n
-C
B
T
g
ro
u
p
s
fo
r
S
tu
d
y
1
a
n
d
S
tu
d
y
2
S
tu
d
y
1
S
tu
d
y
2
O
b
se
rv
ed
d
a
ta
D
ir
ec
t
M
L
es
ti
m
a
te
s
O
b
se
rv
ed
d
a
ta
D
ir
ec
t
M
L
es
ti
m
a
te
s
C
B
T
N
o
n
-C
B
T
C
B
T
N
o
n
-C
B
T
C
B
T
N
o
n
-C
B
T
C
B
T
N
o
n
-C
B
T
N
M
ea
n
( S
.E
.)
N
M
ea
n
(S
.E
.)
M
ea
n
(S
.E
.)
M
ea
n
(S
.E
.)
N
M
ea
n
(S
.E
.)
N
M
ea
n
(S
.E
.)
M
ea
n
(S
.E
.)
M
ea
n
(S
.E
.)
H
A
M
A
p
re
*
6
1
1
8
. 4
8
(0
. 4
9
)
4
2
1
8
. 3
8
(0
. 4
9
)
1
8
. 4
8
(0
. 4
9
)
1
8
. 3
8
(0
. 4
9
)
H
A
M
A
p
o
st
*
5
7
4
. 7
7
(0
. 5
8
)
2
3
7
. 5
2
(0
. 8
2
)
4
. 7
5
(0
. 5
8
)
7
. 5
9
(0
. 7
3
)
B
S
I-
G
S
I
p
re
*
6
1
1
. 6
2
(0
. 0
8
)
3
5
1
. 7
1
(0
. 1
0
)
1
. 6
2
(0
. 0
8
)
1
. 7
3
(0
. 0
9
)
B
S
I-
G
S
I
p
o
st
*
4
7
1
. 0
1
(0
. 1
2
)
2
8
1
. 6
0
(0
. 1
6
)
1
. 0
4
(0
. 1
2
)
1
. 5
9
(0
. 1
5
)
B
S
I-
G
S
I*
2
1
0
. 8
2
(0
. 1
3
)
1
2
1
. 4
3
(0
. 2
7
)
0
. 9
1
(0
. 1
2
)
1
. 4
8
(0
. 2
6
)
3
3
1
. 1
5
$
(0
. 1
4
)
2
6
1
. 5
3
$
(0
. 1
8
)
1
. 1
8
·
(0
. 1
3
)
1
. 4
7
·
(0
. 1
6
)
C
G
S
(0
–
8
)*
1
9
1
. 9
5
(0
. 3
9
)
1
0
2
. 6
0
(0
. 5
0
)
2
. 4
0
(0
. 3
6
)
3
. 2
5
(0
. 4
3
)
3
1
3
. 5
8
$
(0
. 3
5
)
2
3
3
. 7
0
$
(0
. 4
2
)
3
. 4
6
·
(0
. 3
2
)
3
. 7
3
·
(0
. 4
4
)
S
F
3
6
-M
C
#
1
8
4
7
. 5
4
(2
. 5
9
)
1
2
4
2
. 0
4
(3
. 3
8
)
4
5
. 7
2
(2
. 5
3
)
3
9
. 8
8
(2
. 9
6
)
3
3
4
3
. 4
4
$
(1
. 9
4
)
2
5
3
6
. 0
0
$
(2
. 4
8
)
4
3
. 1
4
·
(1
. 8
8
)
3
5
. 6
4
·
(2
. 5
2
)
p
re
,
P
re
-t
re
a
tm
en
t
v
a
lu
es
;
p
o
st
,
p
o
st
-t
re
a
tm
en
t
v
a
lu
es
;
a
ll
o
th
er
v
a
lu
es
a
re
a
t
lo
n
g
-t
er
m
fo
ll
o
w
-u
p
.
*
L
o
w
er
sc
o
re
s
a
re
m
o
re
fa
v
o
u
ra
b
le
.
#
H
ig
h
er
sc
o
re
s
a
re
m
o
re
fa
v
o
u
ra
b
le
.
$
T
h
es
e
C
B
T
a
n
d
n
o
n
-C
B
T
m
ea
n
s
d
iﬀ
er
ed
si
g
n
iﬁ
ca
n
tl
y
o
n
a
M
A
N
O
V
A
(F
(3
,4
7
)=
4
. 0
,
P
=
0
. 0
1
2
).
T
es
te
d
o
n
it
s
o
w
n
th
e
S
F
3
6
-M
C
d
iﬀ
er
en
ce
w
a
s
si
g
n
iﬁ
ca
n
t
(F
(1
,4
9
)=
7
. 0
,
P
=
0
. 0
1
1
).
·
A
co
m
b
in
ed
te
st
o
f
th
e
d
iﬀ
er
en
ce
s
b
et
w
ee
n
th
es
e
C
B
T
a
n
d
n
o
n
-C
B
T
m
ea
n
s
in
A
M
O
S
y
ie
ld
ed
x
2 (
3
)=
9
. 2
,
P
=
0
. 0
2
7
.
T
es
te
d
o
n
it
s
o
w
n
th
e
S
F
3
6
-M
C
d
iﬀ
er
en
ce
w
a
s
si
g
n
iﬁ
ca
n
t
(x
2 (
1
)=
5
. 2
,
P
=
0
. 0
2
2
).
506 R. C. Durham and others
The means of all the observed data and the
DML estimated means are given in Table 4. The
most obvious diﬀerence between the two sets of
means is that in Study 1 the DML means are
worse than the observed means indicating that
patients present at long-term follow-up were
healthier than those absent. In both studies it can
be seen that all the long-term follow-up means
are better in the CBT group than in the non-CBT
group in both the observed and DML means.
Indeed, it appears that the missing data analyses
have had little eﬀect on the CBT/non-CBT dif-
ferences. Table 4 shows that these diﬀerences
were signiﬁcant in Study 2 for both the observed
and DML means. In Study 1 the overall tests of
CBT/non-CBTdiﬀerences were not signiﬁcant at
the 5% level, perhaps because Study 1 had more
missing data, but there was a marginally sig-
niﬁcant diﬀerence on the BSI-GSI in the ob-
served means (F(1,24)=3.44, P=0.076) and in
the DML estimates (x2(1)=3.3, P=0.068). It
may be worth noting that when other long-term
follow-up variables (i.e. the SRT and HAM-A
in Study 1 and the STAI-T in Study 2) replaced
those used in the missing data analyses the DML
estimates consistently showed the CBT groups to
do better than the non-CBT ones, although none
of those variables was signiﬁcant on a univariate
test.
Interim treatment and long-term outcome
Overall, higher levels of interim treatment for
anxiety were related to poorer outcome at long-
term follow-up. Those patients with one or more
clinical diagnoses at long-term follow-up were
signiﬁcantly more likely to have had a lot of in-
terim treatment (5% with no diagnosis versus
28% with one or more diagnoses) (x2(1)=7.8,
P<0.01), and those with no clinical diagnosis
at long-term follow-up were signiﬁcantly more
likely to have received no treatment for anxiety in
the interim period (53%with no diagnosis versus
19% with one or more diagnoses) (x2(1)=10.5,
P<0.01).
DISCUSSION
It must be acknowledged at the outset that our
relatively low overall contact rate, 55% of par-
ticipants in Study 2 but only 30% of participants
in Study 1, opens up the possibility that the
follow-up samples may not be representative of
the original cohorts (Flick, 1988). Exhaustive
analysis revealed no evidence of bias in respect of
a large range of possible variables but we did ﬁnd
a signiﬁcant tendency for a higher proportion
of Study 2 participants to have completed treat-
ment and for a higher proportion of Study 1
participants to have had a positive response to
previous drug treatment and a shorter duration
of disorder at the time of the original trial. The
results may, therefore, present a more positive
picture of overall outcome than is actually
the case, particularly in Study 1. In regard to
the potential bias of ‘ investigator allegiance ’
(Luborsky et al. 1995) it should be noted that
outcome assessments were made by a researcher
who was blind to initial treatment condition.
Evidence of long-term clinical outcome was
collected from several contrasting perspectives
and the results were broadly consistent across
measures with marked diﬀerences in outcome
between the two studies. In Study 1 about 70%
had no diagnosable clinical disorder, about
70% reported a marked improvement since
the original trial and 33–48% were deﬁned as
‘recovered’ on the main outcome measures. In
Study 2, in contrast, only 37% had no diag-
nosable disorder, 43% reported a marked im-
provement since the original trial and 22–39%
were deﬁned as ‘recovered’ on themain outcome
measures. In broad terms, therefore, about two-
thirds of Study 1 patients could be considered as
substantially improved whereas only about one
third of Study 2 patients could be categorized
in this way. In addition, a signiﬁcantly higher
proportion of Study 2 patients reported receiving
a lot of additional treatment over the follow-up
period (3% in Study 1 versus 23% in Study 2).
Interpretation of this diﬀerence between stu-
dies is problematic since there were also diﬀer-
ences in diagnostic selection criteria (1month v. 6
months duration criterion), medication use (free
ofmedication at entry to Study 1), clinical setting
(primary v. secondary care), severity of baseline
measures (greater in Study 2) demographic
characteristics (signiﬁcantly greater social depri-
vation in Study 2) and degree of interim treat-
ment (greater in Study 2). One way of developing
a perspective on the current results is to compare
them with the follow-up study reported by Sei-
vewright and her colleagues (1998) in which 20%
of patients were described as having a poor or
very poor outcome in terms of a standardized
Long-term follow-up of CBT for GAD 507
assessment of health status based on case note
review. They described their cohort of patients –
a mixture of GAD, panic disorder and dysthy-
mia – as intermediate between those seen in
primary care only (as in Study 1) and those re-
ferred to outpatient psychiatric services (as in
Study 2). Their sample shared some features
with Study 1 (medication free at time of treat-
ment, primary care setting, DSM-III diagnosis)
and some features with Study 2 (referral to a
psychiatric service, predominance of patients
from social classes 4 and 5). Taken together the
three cohorts of patients are probably best
viewed as representing increasing degrees of
complexity and severity in the broad spectrum of
neurotic disorder seen in various clinical settings
within themental health services. Various factors
inﬂuence the complexity and severity of clinical
presentation in GAD and we are in the process
of examining prognostic indicators in long-term
follow-up studies of a number of clinical trials of
CBT with anxiety disorders in central Scotland.
As well as diﬀerences in outcome between
Studies 1 and 2 there were also similarities that
are worth noting. The majority of patients in
both studies remained symptomatic at long-term
follow-up, irrespective of treatment received,
and rates of recovery or remission were low (30–
40%). Most patients nonetheless reported some
degree of overall improvement probably because
average levels of symptom severity were lower
than pre-treatment levels. A sizeable minority of
patients (30–40%), mainly from Study 2, had a
generally poor outcome with chronic disability
and high levels of continuing treatment in pri-
mary and secondary care. Taken together these
results underline the therapeutic challenge of
chronic conditions with complex clinical pre-
sentations (Durham et al. 2000). We are still
some way from developing therapies for GAD
that lead to full recovery and all the beneﬁts
that can ﬂow from the remission of symptoms
(cf. Ninian, 2001).
In light of the overall outcome in these two
trials what evidence is there that CBT confers
an advantage relative to other alternatives? In
general, the CBT groups appeared to be better at
long-term follow-up than the non-CBT groups.
Only marginally signiﬁcant diﬀerences were
found when statistical tests were applied to pa-
tient classiﬁcations ; the diﬀerence between the
CBT and non-CBT groups on the BSI caseness
measure approached 5% signiﬁcance on a two-
tailed test and a post hoc test showed that fewer
patients from the CBT as opposed to the non-
CBT group had received a lot of treatment in
the follow-up period. The advantage of the CBT
group was clearer when statistical tests were
applied to quantitativemeasures combining data
from the two studies. Looking at each study
separately there were consistent diﬀerences in
favour of CBT on all the measures of symptom
severity and this pattern remained in analyses
which took account of the missing data. Perhaps
because of the small sample size the CBT ad-
vantage at long-term follow-up in Study 1 was
not statistically signiﬁcant. In Study 2 where
there was less missing data a signiﬁcant CBT
advantage was found in both the observed and
the missing data analyses. CBT, therefore, is
associated with an attenuation of symptoms over
the longer term but not with a reduced prob-
ability of remission.
Conclusion
The overall outcome was signiﬁcantly better in
Study 1 than Study 2. This was probably a func-
tion of the greater severity, chronicity and com-
plexity of presenting problems in Study 2. The
majority of patients in both studies remained
symptomatic at long-term follow-up although
average symptom severity was lower than pre-
treatment levels and most reported some degree
of improvement. For a sizeable minority (30–
40%), mainly in Study 2, overall outcome was
poor with evidence of continued disability and
dependence on medication and/or psychological
treatment. Although approximately 50% of
patients in both CBT and non-CBT groups still
had one or more clinical diagnoses at long-term
follow-up, those in the CBT group had signiﬁ-
cantly lower levels of symptom severity on a
number of psychometric measures. Finally, both
CBT and the complexity and severity of pre-
senting problems appear to inﬂuence the long-
term outcome of GAD.
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